CRIMALDDI: a co-ordinated, rational, and integrated effort to set logical priorities in anti-malarial drug discovery initiatives.
Despite increasing efforts and support for anti-malarial drug R&D, globally anti-malarial drug discovery and development remains largely uncoordinated and fragmented. The current window of opportunity for large scale funding of R&D into malaria is likely to narrow in the coming decade due to a contraction in available resources caused by the current economic difficulties and new priorities (e.g. climate change). It is, therefore, essential that stakeholders are given well-articulated action plans and priorities to guide judgments on where resources can be best targeted.The CRIMALDDI Consortium (a European Union funded initiative) has been set up to develop, through a process of stakeholder and expert consultations, such priorities and recommendations to address them. It is hoped that the recommendations will help to guide the priorities of the European anti-malarial research as well as the wider global discovery agenda in the coming decade.
Boulton
Ian C
IC
Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, UK.
Nwaka
Solomon
S
Bathurst
Ian
I
Lanzer
Michael
M
Taramelli
Donatella
D
Vial
Henri
H
Doerig
Christian
C
Chibale
Kelly
K
Ward
Steve A
SA
D000962:Antimalarials / Q000191:economics* / Q000627:therapeutic use; D055808:Drug Discovery / Q000191:economics* / Q000458:organization & administration; D004351:Drug Resistance; D005062:European Union; D006291:Health Policy; D006292:Health Priorities; D006801:Humans; D008288:Malaria / Q000188:drug therapy / Q000517:prevention & control; D010961:Plasmodium / Q000187:drug effects; D012106:Research / Q000191:economics* / Q000639:trends
D000962:Antimalarials